|Bid||3.7600 x 800|
|Ask||4.2500 x 900|
|Day's Range||3.7800 - 3.9300|
|52 Week Range||2.0200 - 9.0000|
|Beta (3Y Monthly)||2.45|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Microbiome companies face an added complication that other drugmakers may not when trying to maintain an exclusive hold on their products: It’s not possible to patent a naturally occurring substance like plants or bacteria.
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 42.86% and 21.78%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Seres Therapeutics (MCRB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The big shareholder groups in Seres Therapeutics, Inc. (NASDAQ:MCRB) have power over the company. Insiders often own a...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -27.91% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 59 cents. Losses, adjusted for restructuring costs, came to 55 cents per share. The results did not meet Wall Street ...
Big Pharma is rapidly increasing its investments into biotech companies aiming to treat disease by targeting the microbiome. Some are also working on using bacterial strains as drugs.
Microbiome-focused biotech Seres Therapeutics is teaming up with drug giant AstraZeneca to explore how the trillions of bacteria in a person’s gut could help fight cancer.
Roger Pomerantz has been the CEO of Seres Therapeutics, Inc. (NASDAQ:MCRB) since 2014. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of 5.26% and -61.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?